Home / Research library / Retatrutide
Retatrutide (LY3437943): mechanism, evidence and half-life
Retatrutide (development code LY3437943) is an investigational once-weekly peptide from Eli Lilly that activates three receptors: GIP, GLP-1 and glucagon. Its phase 3 programme has published full results from TRIUMPH-1, TRIUMPH-2 and TRANSCEND-T2D-1, while other trials have only sponsor summaries. No regulator has approved it. This page is the reference for its identity, mechanism, pharmacokinetics and study evidence; research-product prices are kept on a separate page.[1],[2],[3],[4],[5]
Compiled by PeptideTech Editors · Evidence sections checked · library records checked · Selected bibliography, not a systematic review
Status as of
| United States | Not approved. No Drugs@FDA application lists retatrutide or LY3437943. FDA states that retatrutide is not a component of an FDA-approved drug, cannot be used in compounding under federal law and has not been found safe and effective for any condition.[6],[7] |
|---|---|
| Other jurisdictions | Lilly’s October 2026 statement says retatrutide has not been reviewed or approved by the FDA or any regulatory agency in the world. PeptideTech has not checked every national register; this line relies on the developer’s statement.[1] |
| Submission plan | On 23 July 2026 Lilly said it plans to submit retatrutide for US approval in the first quarter of 2027, after completing its manufacturing (CMC) data package. That is a stated plan, not a submission or an approval date.[8] |
| Launch date | Not established. No regulator has issued a decision, so no launch date can be stated.[1] |
| Trial access | ClinicalTrials.gov lists a pre-approval expanded access record (NCT07629401) as available. A listing describes a programme; it does not guarantee eligibility or access.[9] |
| Research-labelled products | FDA says it has warned companies that sold unapproved drugs containing retatrutide falsely labelled “for research purposes” or “not for human consumption”. A research listing is not the investigational medicine.[7] |
Retatrutide approval status, availability and trial timeline →
Names, labels and identifiers
“Retatrutide” is the nonproprietary name and LY3437943 (also written LY-3437943) is Lilly’s development code; both appear in the FDA substance record, ChEMBL and the IUPHAR/BPS Guide to Pharmacology deposit in PubChem. FDA’s registry also holds a separate record for retatrutide sodium, so a salt form is a distinct identity that a specification should state.[10],[11],[12],[13]
“GLP-3” is not a hormone, receptor or drug class. Lilly describes it as a scientifically inaccurate nickname for a triple agonist. “Reta” is a search shorthand. Neither label, nor a seller’s catalogue name, establishes what a vial contains.[1]
| Label | What it is |
|---|---|
| GLP-3 | Informal media and seller nickname. Lilly calls it a scientifically inaccurate label: there is no GLP-3 hormone or receptor, and the molecule acts at three existing receptors.[1] |
| Reta | Shorthand used in searches and on seller sites. It is not a registered name and does not identify a substance on its own. |
| GLP-3 R, GLP-3 RT, LAP-3 (R), AP-RTA-3 and similar | Supplier catalogue labels for products the sellers describe as retatrutide. A label is a seller claim to be checked against the specification and a lot report. |
| Triple G | Title of the PubChem compound record linked from the IUPHAR/BPS Guide to Pharmacology deposit that also lists retatrutide and LY3437943.[13] |
- FDA UNII (retatrutide)
- NOP2Y096GV[10]
- FDA UNII (retatrutide sodium)
- LQ42M82ZU6[11]A separate salt-form record: the free peptide and a sodium salt are distinct substance identities.
- ChEMBL
- CHEMBL5095485[12]
- PubChem Substance (IUPHAR deposit)
- SID 507750402[13]
- PubChem Compound
- CID 171390338[14]Computed formula C221H342N46O68, molecular weight 4731 g/mol, for the depicted free molecule.
Three receptor targets
- GIP receptor
- GLP-1 receptor
- glucagon receptor
Retatrutide is a single peptide that is an agonist at three receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. In the discovery paper’s cell assays it showed balanced glucagon- and GLP-1-receptor activity and more GIP-receptor activity. In obese mice, the authors attributed part of the weight effect to glucagon-receptor-mediated increases in energy expenditure.[2]
“Triple agonist” describes the mechanism. It is not a ranking: the number of targets cannot show that one molecule works better than another, which needs a direct randomized comparison.
Pharmacokinetics and half-life
- Reported half-life
- approximately 6 days[15]
- Population
- 72 adults with type 2 diabetes, phase 1b
In the 12-week phase 1b trial in 72 adults with type 2 diabetes, retatrutide pharmacokinetics were dose proportional and the half-life was approximately 6 days. The single ascending dose study in the discovery paper reported a pharmacokinetic profile that supported once-weekly administration in clinical studies.[15],[2]
These estimates come from small early-phase studies of Lilly’s investigational formulation given under the trial protocols. They describe how the clinical-trial material behaved in those participants; they are not a schedule and do not transfer to a research-labelled product of unverified identity, amount or formulation.
Clinical evidence: dated study table
The table lists each trial with its population, duration, comparator and primary endpoint, because a percentage means little without them. TRIUMPH-1 and TRIUMPH-2 used a treatment-regimen estimand, which counts what happened regardless of whether people stopped treatment; the TRANSCEND-T2D-2 topline uses an efficacy estimand, which estimates the effect had everyone stayed on treatment. Those are different questions.[3],[4],[21]
Adverse events matter as much as averages. Across the published trials, gastrointestinal events were the most common; the phase 2 obesity trial reported dose-related heart-rate increases, and TRIUMPH-2 reported more hypotension, dysaesthesia and discontinuation for adverse events at the higher arms than with placebo.[16],[3],[4]
| Study · registry | Population · duration | Comparator · primary endpoint | Reported result | Report status |
|---|---|---|---|---|
| Phase 1b (multiple ascending)NCT04143802 | 72 adults with type 2 diabetes12 weeks | Placebo and dulaglutideSafety, pharmacokinetics | Half-life approximately 6 days; dose-proportional pharmacokinetics; gastrointestinal events most common.[15] | Peer-reviewed (Lancet 2022) |
| Phase 2 obesityNCT04881760 | 338 adults with obesity or overweight, without diabetes48 weeks | PlaceboBody weight at 24 weeks | At 48 weeks, mean change −24.2% in the highest studied arm vs −2.1% with placebo; dose-related gastrointestinal events and heart-rate increases.[16] | Peer-reviewed (NEJM 2023) |
| Phase 2 type 2 diabetesNCT04867785 | 281 adults with type 2 diabetes36 weeks | Placebo and dulaglutideHbA1c at 24 weeks | HbA1c change up to −2.02% vs −0.01% with placebo at 24 weeks; body weight change up to −16.94% at 36 weeks.[17] | Peer-reviewed (Lancet 2023) |
| TRANSCEND-T2D-1 (phase 3)NCT06354660 | 537 adults with type 2 diabetes on diet and exercise alone40 weeks | PlaceboHbA1c at 40 weeks | HbA1c −1.69% to −1.94% vs −0.81%; body weight −11.5% to −15.3% vs −2.6% (treatment-regimen estimand).[5] | Peer-reviewed (Lancet 2026) |
| TRIUMPH-1 (phase 3)NCT05929066 | 2,339 adults with obesity or overweight, without diabetes; knee osteoarthritis and sleep apnoea subgroups80 weeks | PlaceboBody weight; knee pain and apnoea–hypopnoea index in subgroups | Mean weight change −17.6%, −23.7% and −25.0% across three active arms vs −3.9% with placebo (treatment-regimen estimand); gastrointestinal events most common.[3] | Peer-reviewed (NEJM 2026) |
| TRIUMPH-2 (phase 3)NCT05929079 | 1,152 adults with type 2 diabetes and BMI 27 or higher80 weeks | PlaceboBody weight at 80 weeks | Mean weight change −11.9%, −16.8% and −18.8% vs −5.1% (treatment-regimen estimand); discontinuation for adverse events 4%–12% across arms vs 5%.[4] | Peer-reviewed (Lancet 2026) |
| TRIUMPH-3 (phase 3)NCT05882045 | About 1,949 adults with severe obesity and established cardiovascular disease (registry: 1,946 enrolled)80 weeks | PlaceboBody weight | Sponsor topline only. Cardiovascular event hazard-ratio confidence intervals included no difference, so these data do not establish cardiovascular benefit or harm.[8],[18] | Sponsor topline (23 July 2026); no full paper found |
| TRIUMPH-4 (phase 3)NCT05931367 | 445 adults with obesity or overweight and knee osteoarthritis, without diabetes68 weeks | PlaceboKnee pain score and body weight | Sponsor topline only. The release cites NCT05869903, which ClinicalTrials.gov lists as an orforglipron study; the TRIUMPH-4 registry record is NCT05931367.[19],[20] | Sponsor topline (11 December 2025); no full paper found |
| TRANSCEND-T2D-2 (phase 3, head-to-head)NCT06260722 | Adults with type 2 diabetes on metformin with or without an SGLT2 inhibitor (sponsor: 1,298 randomized)80 weeks | Semaglutide 2 mg once weekly (open label)HbA1c at 80 weeks | Sponsor topline, efficacy estimand: HbA1c −2.2% in both retatrutide arms vs −1.8%; body weight −19.5% and −20.9% vs −9.4%. The registry still lists the study as active, not recruiting.[21],[22] | Sponsor topline (28 October 2026); not peer reviewed |
| TRIUMPH-5 (phase 3, head-to-head)NCT06662383 | Adults with obesity, with or without type 2 diabetes (registry: 800)Registry primary completion estimated November 2026 | TirzepatideBody weight | No results posted or published when checked.[23] | Ongoing (active, not recruiting) |
Direct comparisons: retatrutide vs tirzepatide · retatrutide vs semaglutide · three-way evidence comparison
Limitations and open questions
- Whether, when and for which uses any regulator will authorize retatrutide. A submission plan is not a decision.
- Full peer-reviewed results for TRIUMPH-3, TRIUMPH-4 and TRANSCEND-T2D-2; their sponsor summaries have not been through journal review.
- How retatrutide compares directly with tirzepatide. TRIUMPH-5 is the registered head-to-head trial and has no results yet.
- Long-term cardiovascular and kidney outcomes; the dedicated outcomes trial (NCT06383390) is still running.
- The storage conditions and shelf life of the clinical-trial formulation, which are not public.
- The identity, amount and purity of any research-labelled vial, which a name, label or this research record cannot establish.
Laboratory properties and storage
Research suppliers list retatrutide as a lyophilized powder. The storage conditions they state are their own instructions, not results of a published stability study. A PubMed search on 5 November 2026 found no stability study of retatrutide in powder or solution; a 2026 review lists formulation stability among the open pharmaceutical-development questions.[24]
Retatrutide storage evidence: supplier statements and what is unknown →
Research-product listings
Research-use listings are commercial products, separate from the investigational medicine studied above. A listing name, a certificate of analysis or this research record does not establish that a vial matches the trial material. See current Retatrutide research-product prices by exact package and source date.
Retatrutide questions
What is the difference between retatrutide, reta and GLP-3?
Retatrutide is the nonproprietary name of Lilly’s investigational molecule LY3437943. “Reta” is shorthand and “GLP-3” is an informal nickname that Lilly calls scientifically inaccurate; there is no GLP-3 receptor. Seller labels such as GLP-3 RT are claims to be checked against a specification and lot report, not identity proof.[1],[10]
What receptors does retatrutide target?
Three: the GIP receptor, the GLP-1 receptor and the glucagon receptor. In the discovery paper’s cell assays it showed balanced glucagon- and GLP-1-receptor activity and more GIP-receptor activity.[2]
What does the reported half-life of about 6 days mean?
In a 12-week phase 1b trial in 72 adults with type 2 diabetes, the measured half-life of Lilly’s investigational formulation was approximately 6 days, which the authors said suits once-weekly administration in trials. It describes those participants and that material; it is not a schedule and says nothing about a research-labelled product.[15]
Source ledger
Every source below was opened and checked on November 5, 2026. Sponsor announcements are labelled and have not been through journal review.
- Lilly: What to know about retatrutide (last updated October 2026) · Sponsor statement · checked
- Coskun T et al. LY3437943, a novel triple glucagon, GIP and GLP-1 receptor agonist: from discovery to clinical proof of concept. Cell Metab 2022;34:1234–1247 · Peer-reviewed pharmacology and phase 1 study · checked
- Jastreboff AM et al. Retatrutide, a triple hormone receptor agonist, for treatment of obesity (TRIUMPH-1). N Engl J Med 2026;395:1781–1793 · Peer-reviewed clinical trial · checked
- Bellido V et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2). Lancet 2026;408:1455–1472 · Peer-reviewed clinical trial · checked
- Bajaj HS et al. Retatrutide in type 2 diabetes inadequately controlled with diet and exercise (TRANSCEND-T2D-1). Lancet 2026;407:2402–2413 · Peer-reviewed clinical trial · checked
- Drugs@FDA via openFDA: no application lists retatrutide or LY3437943 as an active ingredient · US regulator database search · checked
- FDA: concerns with unapproved GLP-1 drugs used for weight loss (content current as of 1 October 2026) · US regulator · checked
- Lilly: TRIUMPH-2 and TRIUMPH-3 topline results and US submission plan (23 July 2026) · Sponsor announcement; not peer reviewed · checked
- ClinicalTrials.gov NCT07629401: pre-approval expanded access (listed as available) · Trial registry record · checked
- FDA Global Substance Registration System: retatrutide, UNII NOP2Y096GV · US regulator substance record · checked
- FDA Global Substance Registration System: retatrutide sodium, UNII LQ42M82ZU6 · US regulator substance record · checked
- ChEMBL CHEMBL5095485: retatrutide (synonyms LY3437943, LY-3437943) · Drug-development database record · checked
- PubChem Substance 507750402 (IUPHAR/BPS Guide to Pharmacology deposit: retatrutide, LY3437943, Triple G) · Chemical identity record · checked
- PubChem Compound 171390338: computed formula and molecular weight · Chemical identity record · checked
- Urva S et al. LY3437943 in people with type 2 diabetes: phase 1b multiple-ascending dose trial. Lancet 2022;400:1869–1881 · Peer-reviewed clinical trial · checked
- Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med 2023;389:514–526 · Peer-reviewed clinical trial · checked
- Rosenstock J et al. Retatrutide for people with type 2 diabetes: phase 2 trial conducted in the USA. Lancet 2023;402:529–544 · Peer-reviewed clinical trial · checked
- ClinicalTrials.gov NCT05882045: TRIUMPH-3 (completed) · Trial registry record · checked
- Lilly: TRIUMPH-4 topline results (11 December 2025) · Sponsor announcement; not peer reviewed · checked
- ClinicalTrials.gov NCT05931367: TRIUMPH-4 (completed) · Trial registry record · checked
- Lilly: TRANSCEND-T2D-2 head-to-head topline results versus semaglutide (28 October 2026) · Sponsor announcement; not peer reviewed · checked
- ClinicalTrials.gov NCT06260722: TRANSCEND-T2D-2, retatrutide versus semaglutide (active, not recruiting) · Trial registry record · checked
- ClinicalTrials.gov NCT06662383: TRIUMPH-5, retatrutide versus tirzepatide (active, not recruiting) · Trial registry record · checked
- Retatrutide as a unimolecular GIP/GLP-1/glucagon receptor tri-agonist: molecular design, pharmaceutical development and phase 3 evidence. Pharmaceutics 2026;18:1277 · Peer-reviewed narrative review (secondary source) · checked
Molecular formula, weight & structure
- Molecular formula (MF)
- C221H342N46O68
- Molecular weight (MW)
- 4731 g/mol
- PubChem compound ID
- 171390338
- Record title
- Triple G
This structure is linked through the IUPHAR depositor record (SID 507750402), whose compound title is Triple G. It represents the referenced molecule, not a tested supplier batch.
Source: PubChem CID 171390338 · retrieved 2026-09-21 · Identity cross-reference
Chemical identifiers and source data
- IUPAC name
- 20-[[(1S)-4-[2-[2-[2-[[(5S)-5-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-2-methylpropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-2,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]hexanoyl]amino]-6-[[(2S)-1-[[(2S)-5-amino-1-[[1-[[(2S)-1-[[(2S)-1-[[(3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-[[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-2-methyl-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-6-oxohexyl]amino]-2-oxoethoxy]ethoxy]ethylamino]-1-carboxy-4-oxobutyl]amino]-20-oxoicosanoic acid
- InChIKey
- MLOLQJNKXBNWFW-SAGGEDDASA-N
- SMILES
- CC[C@H](C)C(C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N3CCC[C@H]3C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H](C)NC(=O)C(C)(C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)CC[C@@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@](C)(CC(C)C)NC(=O)C([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H](CC7=CC=C(C=C7)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC8=CC=CC=C8)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)C(C)(C)NC(=O)[C@H](CC9=CC=C(C=C9)O)N
Identifiers
- PubChem CID
- 171390338
- InChIKey
- MLOLQJNKXBNWFW-SAGGEDDASA-N
Other names and development codes: LY3437943
Calculated molecular descriptors
| Monoisotopic (exact) mass | 4728.4718 Da |
|---|---|
| Heavy atoms | 335 |
| Hydrogen-bond donors | 58 |
| Hydrogen-bond acceptors | 64 |
| Rotatable bonds | 159 |
| Topological polar surface area | 1783.8 Ų |
| Calculated logP (Crippen) | -11.40 |
| Rings | 9 |
| Stereocenters | 38 |
| Formal charge | 0 |
Computed with RDKit from the published SMILES (Crippen logP, topological polar surface area). Calculated descriptors are not measured properties of a supplied batch.
US regulatory status & drug development
Drugs@FDA lists no NDA, BLA or ANDA with retatrutide as an active ingredient (names searched: RETATRUTIDE, LY3437943; checked October 7, 2026). Research-labelled Retatrutide listings are not FDA-approved drugs.
An FDA approval covers a defined medicine, formulation and labelled use. It does not extend to research-labelled material sold under the same compound name. Identity basis: Investigational INN; development code LY3437943 also searched.
Source: Drugs@FDA via openFDA (active-ingredient search for RETATRUTIDE, LY3437943) · checked . openFDA data are not intended for clinical decisions.
Registered clinical trials
Studies registered on ClinicalTrials.gov that list Retatrutide as an intervention. Studies that only measure the molecule as a biomarker, or use it only as a comparator or background arm for another drug, are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.
34 registered studies matched, 11 currently active or recruiting, 2 with results posted on ClinicalTrials.gov.
- By highest phase
- Phase 3 · 14Phase 2 · 4Phase 1 · 15Not applicable · 1
- By registry status
- Completed · 22Active Not Recruiting · 9Recruiting · 2Available · 1
| Study | Phase · status | Conditions | Sponsor · size |
|---|---|---|---|
| Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are OverweightNCT07467447 · start 2026-02-15 · primary completion 2027-03-14 | Phase 2Recruiting | Obesity | Hudson Biotech300 participants |
| A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or OverweightNCT07357415 · start 2026-01-24 · primary completion 2028-10 | Phase 3Active Not Recruiting | Obesity · Overweight | Eli Lilly and Company600 participants |
| A Study of Retatrutide (LY3437943) in Participants With Obesity or OverweightNCT07232719 · start 2025-11-17 · primary completion 2027-07 | Phase 3Active Not Recruiting | Obesity · Overweight | Eli Lilly and Company250 participants |
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)NCT07165028 · start 2025-10-15 · primary completion 2030-08 | Phase 3Recruiting | Metabolic Dysfunction-Associated Steatotic Liver Disease | Eli Lilly and Company4500 participants |
| A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes MellitusNCT06982859 · start 2025-06-02 · primary completion 2027-01 | Phase 1Active Not Recruiting | Diabetes Mellitus · Insulin Sensitivity | Eli Lilly and Company95 participants |
| A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back PainNCT07035093 · start 2025-05-29 · primary completion 2027-09 | Phase 3Active Not Recruiting | Obesity · Overweight · Chronic Low Back Pain (CLBP) | Eli Lilly and Company586 participants |
| A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With ObesityNCT06859268 · start 2025-03-05 · primary completion 2028-04 | Phase 3Active Not Recruiting | Obesity | Eli Lilly and Company643 participants |
| A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have ObesityNCT06662383 · start 2024-11-01 · primary completion 2026-11 | Phase 3Active Not Recruiting | Obesity | Eli Lilly and Company800 participants |
| The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)NCT06383390 · start 2024-04-30 · primary completion 2029-02 | Phase 3Active Not Recruiting | Atherosclerotic Cardiovascular Disease (ASCVD) · Chronic Kidney Disease (CKD) | Eli Lilly and Company10000 participants |
| Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)NCT06297603 · start 2024-03-15 · primary completion 2026-10 | Phase 3Active Not Recruiting | Type 2 Diabetes | Eli Lilly and Company320 participants |
Show 24 more registered studies
| Study | Phase · status | Conditions | Sponsor · size |
|---|---|---|---|
| Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)NCT06260722 · start 2024-02-21 · primary completion 2026-08-27 | Phase 3Active Not Recruiting | Diabetes Mellitus, Type 2 | Eli Lilly and Company1250 participants |
| A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to HypoglycemiaNCT06982846 · start 2025-06-06 · primary completion 2026-05-04 | Phase 1Completed | Type 2 Diabetes Mellitus | Eli Lilly and Company80 participants |
| To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy ParticipantsNCT06808802 · start 2025-02-03 · primary completion 2025-04-15 | Phase 1Completed | Healthy | Eli Lilly and Company30 participants |
| Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)NCT06354660 · start 2024-04-10 · primary completion 2026-01-22 | Phase 3Completed | Diabetes Type 2 | Eli Lilly and Company537 participants |
| A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943NCT06313528 · start 2024-03-20 · primary completion 2025-08-26 | Phase 1Completed | Obesity | Eli Lilly and Company85 participants |
| A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or ObeseNCT06039826 · start 2023-09-12 · primary completion 2024-07-11 | Phase 1Completed | Overweight | Eli Lilly and Company46 participants |
| A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the KneeNCT05931367 · start 2023-08-01 · primary completion 2025-11-14 | Phase 3Completed | Obesity · Overweight · Osteo Arthritis Knee | Eli Lilly and Company445 participants |
| A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection DevicesNCT06003465 · start 2023-08-29 · primary completion 2024-02-08 | Phase 1Completed | Healthy | Eli Lilly and Company57 participants |
| A Study of LY3437943 in Participants With Impaired and Normal Liver FunctionNCT05916560 · start 2023-07-13 · primary completion 2025-03-02 | Phase 1Completed | Healthy · Hepatic Insufficiency | Eli Lilly and Company43 participants |
| A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or OverweightNCT05929066 · start 2023-07-10 · primary completion 2026-04-06 | Phase 3Completed | Obesity · Overweight · Osteoarthritis, Knee · Obstructive Sleep Apnea | Eli Lilly and Company2335 participants |
| A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or OverweightNCT05929079 · start 2023-07-11 · primary completion 2026-06-16 | Phase 3Completed | Type 2 Diabetes · Obesity · Overweight · Obstructive Sleep Apnea | Eli Lilly and Company1152 participants |
| A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesNCT05936151 · start 2023-07-20 · primary completion 2025-10-01 | Phase 2Completed | Overweight or Obesity · CKD · Type 2 Diabetes | Eli Lilly and Company146 participants |
| A Study of LY3437943 in Healthy Participants With a High Body Mass IndexNCT05959096 · start 2023-07-18 · primary completion 2024-07-25 | Phase 1Completed | Healthy | Eli Lilly and Company85 participants |
| A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular DiseaseNCT05882045 · start 2023-05-30 · primary completion 2026-04-16 | Phase 3Completed | Obesity · Cardiovascular Diseases | Eli Lilly and Company1946 participants |
| A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male ParticipantsNCT05757531 · start 2023-03-17 · primary completion 2023-06-23 | Phase 1Completed | Healthy | Eli Lilly and Company7 participants |
| A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal FunctionNCT05611957 · start 2022-11-16 · primary completion 2023-09-05 | Phase 1Completed | Healthy · Renal Insufficiency | Eli Lilly and Company29 participants |
| A Study of LY3437943 in Chinese Participants With Obesity Or OverweightNCT05548231 · start 2022-10-24 · primary completion 2023-07-27 | Phase 1Completed | Overweight · Obesity | Eli Lilly and Company32 participants |
| A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese ParticipantsNCT05445232 · start 2022-07-08 · primary completion 2023-02-24 | Phase 1Completed | Obesity | Eli Lilly and Company32 participants |
| A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)NCT04823208 · start 2021-05-24 · primary completion 2022-06-23 | Phase 1Completed | Diabetes Mellitus, Type 2 | Eli Lilly and Company64 participants |
| A Study of LY3437943 in Participants With Type 2 DiabetesNCT04867785 · start 2021-05-13 · primary completion 2022-07-08 | Phase 2CompletedResults posted 2023-07-03 | Type 2 Diabetes | Eli Lilly and Company281 participants |
| A Study of LY3437943 in Participants Who Have Obesity or Are OverweightNCT04881760 · start 2021-05-20 · primary completion 2022-05-16 | Phase 2CompletedResults posted 2023-09-13 | Obesity · Overweight | Eli Lilly and Company338 participants |
| A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)NCT04143802 · start 2019-12-18 · primary completion 2020-12-28 | Phase 1Completed | Diabetes Mellitus, Type 2 | Eli Lilly and Company72 participants |
| A Safety Study of LY3437943 Given as a Single Injection in Healthy ParticipantsNCT03841630 · start 2019-03-13 · primary completion 2019-07-25 | Phase 1Completed | Healthy | Eli Lilly and Company45 participants |
| Pre-approval Expanded Access of Retatrutide (LY3437943)NCT07629401 | Not applicableAvailable | Obesity · Obesity-related Complications | Eli Lilly and CompanyEnrollment not listed |
Registry check 2026-10-09 · Run this search on ClinicalTrials.gov
Human intervention studies
Selected studies in which participants received Retatrutide, with their indexed or reviewed study type. Check the original article for the formulation, population and controls. Studies that only measured the molecule, or used it as a comparator, are listed separately below and are not counted as intervention studies.
- Human study · PubMed trial index Compound given to participants
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
Jastreboff AM, Kaplan LM, Frías JP et al. · The New England journal of medicine · 2023
Randomized, double-blind, placebo-controlled phase 2 study in 338 adults with obesity. Reports 48-week weight outcomes and adverse events; vendor research products were not evaluated.
PMID 37366315 · DOI: 10.1056/NEJMoa2301972 · Registration NCT04881760
- Mixed laboratory and early human research Compound given to participants
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.
Coskun T, Urva S, Roell WC et al. · Cell metabolism · 2022
Discovery and translational report combining receptor experiments, mouse data and an early human dose-escalation study. These stages answer different questions.
PMID 35985340 · DOI: 10.1016/j.cmet.2022.07.013
- Human study · PubMed trial index Compound given to participants
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.
Sanyal AJ, Kaplan LM, Frias JP et al. · Nature medicine · 2024
PMID 38858523 · DOI: 10.1038/s41591-024-03018-2 · Registration NCT04881760
- Human study · PubMed trial index Compound given to participants
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.
Bajaj HS, Welch M, Shah P et al. · Lancet (London, England) · 2026
PMID 42250575 · DOI: 10.1016/S0140-6736(26)00967-0 · Registration NCT06354660
- Human study · PubMed trial index Compound given to participants
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
Rosenstock J, Frias J, Jastreboff AM et al. · Lancet (London, England) · 2023
PMID 37385280 · DOI: 10.1016/S0140-6736(23)01053-X · Registration NCT04867785
- Human study · PubMed trial index Compound given to participants
Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.
Coskun T, Wu Q, Schloot NC et al. · The lancet. Diabetes & endocrinology · 2025
PMID 40609566 · DOI: 10.1016/S2213-8587(25)00092-0 · Registration NCT04867785
- Human study · PubMed trial index Compound given to participants
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.
Urva S, Coskun T, Loh MT et al. · Lancet (London, England) · 2022
PMID 36354040 · DOI: 10.1016/S0140-6736(22)02033-5 · Registration NCT04143802
Preclinical research, reviews & other publications
Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.
- Review · secondary evidence
Retatrutide-A Game Changer in Obesity Pharmacotherapy.
Katsi V, Koutsopoulos G, Fragoulis C et al. · Biomolecules · 2025
PMID 40563436 · DOI: 10.3390/biom15060796
- Research publication · design requires review
Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.
Giblin K, Kaplan LM, Somers VK et al. · Diabetes, obesity & metabolism · 2026
PMID 41090431 · DOI: 10.1111/dom.70209
Retatrutide supplier sources
Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.
Retatrutide for sale: compare prices, sizes and forms from every tracked supplier →
| Supplier | Recorded packages | Example source listing |
|---|---|---|
| Blank PeptidesUSD | 10mg Vial · 20mg Vial · 30mg Vial · 15mg Vial4 recorded offers | 10mg Vial · $105.00Stale observation · Checked Sep 30, 2026Supplier listing, Retatrutide 10mg Vial, Blank Peptides, opens in a new tab |
| American PeptidesUSD | 10mg Vial · 20mg Vial · 30mg Vial · 48mg Vial · 60mg Vial5 recorded offers | 10mg Vial · $105.00Checked Nov 6, 2026Supplier listing, Retatrutide 10mg Vial, American Peptides, opens in a new tab |
| Amino ClubUSD | 10mg Vial · 20mg Vial · 30mg Vial3 recorded offers | 10mg Vial · $69.99Stale observation · Checked Oct 14, 2026Supplier listing, Retatrutide 10mg Vial, Amino Club, opens in a new tab |
| Nova Peptide SupplyUSD | 5mg Vial · 10mg Vial · 20mg Vial · 40mg Vial · 50mg Vial5 recorded offers | 5mg Vial · $59.99Checked Nov 6, 2026Supplier listing, Retatrutide 5mg Vial, Nova Peptide Supply, opens in a new tab |
| LA PeptidesUSD | 10mg Vial · 20mg Vial · 30mg Vial3 recorded offers | 10mg Vial · $94.99Checked Nov 3, 2026Supplier listing, Retatrutide 10mg Vial, LA Peptides, opens in a new tab |
Reference sources & further reading
- PubChem compound record 171390338 — chemical identity and structure.
- Wikipedia: Retatrutide — Background encyclopedia; not a primary clinical source.
- Grokipedia: Retatrutide — Background encyclopedia; not a primary clinical source.
The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.
Search for additional research
These links run searches; their results have not been individually reviewed and can include unrelated compounds.
Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.
Related research profiles
Cagrilintide
C194H312N54O59S2
4409 g/mol · PubChem CID 171397054
5 selected publications · 4 human intervention studies · 40 registered trials
Protein / peptide · highest stage: Phase 3
Eloralintide
Molecular identity needs further verification
4 selected publications · 3 human intervention studies · 22 registered trials
Liraglutide
C172H265N43O51
3751 g/mol · PubChem CID 16134956
7 selected publications · 4 human intervention studies · 33 registered trials
US: active ingredient of an FDA-approved medicine · Drugs@FDA
Protein / peptide · highest stage: Approved in at least one jurisdiction (ChEMBL phase 4)
Mazdutide
C207H317N45O65
4476 g/mol · PubChem CID 167312357
7 selected publications · 6 human intervention studies · 40 registered trials
Protein / peptide · highest stage: Phase 3
Orforglipron Capsules
C48H48F2N10O5
883.0 g/mol · PubChem CID 137319706
8 selected publications · 6 human intervention studies · 40 registered trials
Small molecule · highest stage: Phase 3
Semaglutide
C187H291N45O59
4114 g/mol · PubChem CID 56843331
8 selected publications · 5 human intervention studies · 34 registered trials
US: active ingredient of an FDA-approved medicine · Drugs@FDA
Protein / peptide · highest stage: Approved in at least one jurisdiction (ChEMBL phase 4)